Month: September 2026

IRVINE, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) — Beta Bionics, Inc. (Nasdaq: BBNX) today announced the pricing of an underwritten public offering of 7,652,175 shares of its common stock at a price to the public of $17.25 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 1,043,484 shares of common stock at a purchase price of $17.2499 per share, which equals the public offering price per share of the common stock less the $0.0001 exercise price per share of each pre-funded warrant. The gross proceeds from this offering are expected to be $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Beta Bionics. The offering is expected to close on or about September 17, 2026, subject to customary closing conditions. In addition, Beta Bionics has granted the underwriters for the offering a 30-day option to purchase up to 1,304,348 additional shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Beta Bionics expects to use the net proceeds from this offering for general corporate purposes, which may include costs associated with the commercialization of Mint^TM, including expansion of Beta Bionics’ manufacturing facilities, research and development and clinical development, investment in product enhancements, potential strategic opportunities and working capital and operating expenses.

J.P. Morgan, Piper Sandler, Wells Fargo Securities and Leerink Partners are acting as the joint book-running managers for the offering.

The shares of common stock and pre-funded warrants described above are being offered by Beta Bionics pursuant to a shelf registration statement on Form S-3 that was filed by Beta Bionics with the Securities and Exchange Commission (SEC) on February 24, 2026 and automatically became effective upon filing. A final prospectus supplement related to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; or from Piper Sandler & Co., 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, Attention: Prospectus Department, by telephone at (800) 747-3924, or by email at prospectus@psc.com; or from Wells Fargo Securities, LLC, Attention: Wells Fargo Securities, 90 South 7th Street, 5th Floor, Minneapolis, Minnesota 55402, by telephone at 800-645-3751 (option #5), by email at WFScustomerservice@wellsfargo.com; or from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD.

Cautionary Note on Forward-Looking Statements

Certain statements in this press release are forward-looking statements that involve a number of risks and uncertainties. These statements may be identified by introductory words such as “may,” “expects,” “goal,” “intend,” “will,” “would,” “subject to” or words of similar meaning, or by the fact that they do not relate strictly to historical or current facts. Such forward-looking statements include statements regarding Beta Bionics’ expectations with respect to the completion, timing and size of the public offering, and the use of proceeds from the offering. For such statements, Beta Bionics claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Beta Bionics’ expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, changes in market conditions, the risk that the offering will not be consummated on the timing contemplated or otherwise, and the satisfaction of customary closing conditions related to the offering, as well as the risks and uncertainties discussed in the preliminary prospectus supplement for the offering and other risks and uncertainties disclosed in Beta Bionics’ filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on February 24, 2026, as updated by its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the SEC on July 29, 2026, and other filings that Beta Bionics may make from time to time with the SEC. These forward-looking statements represent Beta Bionics’ judgment as of the time of this release. Beta Bionics disclaims any intent or obligation to update these forward-looking statements, other than as may be required under applicable law.

Investor Relations:
Blake Beber
Head of Investor Relations
ir@betabionics.com

Media and Public Relations:
Felicia Sanborn
Vice President of Marketing
media@betabionics.com

Phoenix, AZ, Sept. 15, 2026 (GLOBE NEWSWIRE) — InnSuites Hospitality Trust (NYSE American: IHT) announced record Fiscal 2027 (February 1, 2026 through January 31, 2027) First Fiscal Half Total Revenues of $4,099,593.

Consolidated Net Income before non-cash items primarily consisting of depreciation was $120,280 for the 2027 First Fiscal Half ended July 31, 2026. This represents an increase of $178,057 over the prior year.

Combined Hotel Occupancy was 83.42% for the First Fiscal Half of Fiscal Year 2027, which was approximately a 3.04% increase from the prior First Fiscal Half, while the Revenue Per Available Room and Suites (REVPAR), modestly increased from $78.48 to $79.66 over this same period.

IHT hotel operations were strong in the 2026 Fiscal Year ended January 31, 2026, and contributed to a steady First Half in the current 2027 Fiscal Year. Combined Hotel August Revenue for both hotels was $513,145, which led to total Hotel Revenue of approximately $4.5 million for the First Seven Fiscal Months of Fiscal 2027, a combined record. IHT’s strong hotel operating results are reflected in three of the five most recent Fiscal Years profitable, even after accounting for substantial depreciation and other non-cash expenses. These are positive signs for InnSuites, as progress remains strong, despite 2026 Travel Industry uncertainty.

On August 19, 2026, the Trust increased its shareholders’ equity by $3 million and reduced debt by $3 million.

InnSuites Hospitality Trust continues to explore diversification opportunities and opportunities to increase Equity, potentially including a merger or reverse merger, which is of high interest.

The continued growing demand for electricity from data centers plus the influx of electric vehicles, as well as projected growing needs for artificial intelligence, increased demand for electricity over the next five years is projected to approximately double, and bodes well for the IHT investment in UniGen Power, Inc. This product is a potentially power industry disruptive economical, relatively clean energy, cost effective electric generation innovation. Even though it is high risk, UniGen offers IHT high upside potential.

On February 20, 2026, James Wirth, IHT President, was elected Chairman, CEO, and President of UniGen, while Marc Berg, IHT EVP, was elected as Vice Chairman, EVP, and Secretary/Treasurer of UniGen, with plans to rejuvenate the UniGen progress, while also holding all the UniGen Board seats.

On March 5, 2025, REF, an investment entity owned by the chairman and family of IHT majority IHT shareholder, purchased IBC Hotels, LLC, and hired RRF LLLP, the management company subsidiary of InnSuites Hospitality Trust (IHT), to manage the rebirth of IBC. In the process, RRF LLLP, obtained a five-year option to purchase, at cost, IBC Hotels, LLC. This option is believed to provide IHT a valuable upside opportunity, if successful, to profit from the revitalization of InnDependent Boutique Collection (IBC Hotels).

IHT management believes that due to real estate held on the books of IHT at book values significantly below current market value, due to clean energy diversification high profit potential ahead, IBC independent hotel services prospects, a potential merger or reverse merger future, plus improving hospitality profitability before non-cash depreciation and other non-cash items, along with the recent increase of IHT equity of $3 million, the IHT future looks bright.

IHT future plans include continuation of its uninterrupted annual dividend, beginning in its inception in 1971, with the next dividend tentatively scheduled for February 15, 2027, at the beginning of the 2028 Fiscal Year.

Management believes that the Trust’s hotel operating results, real estate assets, capitalization initiatives, and strategic alternatives provide a positive basis for future of the Trust. There can be no assurance that any of these initiatives will be successful, that the Trust will complete any equity-enhancing transaction, or that the Trust will regain or maintain compliance with NYSE American continued listing standards.

For more information, visit www.innsuitestrust.com and www.innsuites.com.

Forward-Looking Statements

With the exception of historical information, matters discussed in this news release may include “forward-looking statements” within the meaning of the federal securities laws. Forward-looking statements include, without limitation, statements regarding the Trust’s intended submission of a compliance plan to NYSE American; the Trust’s ability to regain compliance with NYSE American continued listing standards; potential actions to increase stockholders’ equity; potential conversion of related-party indebtedness into IHT equity; potential capital-raising, capitalization restructuring, or strategic transactions; potential merger or reverse merger opportunities; operating initiatives; hotel operating trends; future annual dividends; diversification opportunities; opportunities involving IBC Hotels, LLC and UniGen Power, Inc.; and expected costs, benefits, timing, or results of any of the foregoing.

Actual developments, business decisions, results, and future actions may differ materially from those expressed or implied by such forward-looking statements. Important factors, among others, that could cause actual results and future actions to differ materially include: NYSE American’s review of the Trust’s compliance plan; the Trust’s ability to complete any equity-enhancing transaction; the Trust’s ability to regain and maintain compliance with NYSE American continued listing standards; the availability, terms, and timing of financing or capitalization alternatives; the outcome of any related-party transaction review; accounting treatment of proposed transactions; required board, committee, NYSE American, shareholder, or other approvals; market conditions; hotel operating results; seasonality; liquidity needs; the outcome of any merger or reverse merger or strategic transaction discussions; the timing and success of potential diversification initiatives; risks relating to IBC Hotels, LLC and UniGen Power, Inc.; economic effects of international conflicts, tariffs, inflation, interest rates, travel industry conditions, and other macroeconomic factors; and the risks described in the Trust’s filings with the Securities and Exchange Commission.

The Trust undertakes no obligation to update any forward-looking statement contained in this news release to reflect events or circumstances after the date of this news release, except as required by applicable law.

FOR FURTHER INFORMATION:

Marc Berg, Executive Vice President
602-944-1500
email: mberg@innsuites.com

INNSUITES HOSPITALITY CENTRE
1730 E. NORTHERN AVENUE, #122
Phoenix, Arizona 85020
Phone: 602-944-1500